Pfizer Inc. $PFE Stock Holdings Lifted by Causeway Capital Management LLC

Causeway Capital Management LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 5.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,072,047 shares of the biopharmaceutical company’s stock after acquiring an additional 108,735 shares during the quarter. Causeway Capital Management LLC’s holdings in Pfizer were worth $52,796,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its stake in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. United Bank grew its holdings in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Prospera Financial Services Inc grew its holdings in shares of Pfizer by 108.6% during the 2nd quarter. Prospera Financial Services Inc now owns 179,393 shares of the biopharmaceutical company’s stock valued at $4,349,000 after acquiring an additional 93,382 shares in the last quarter. Finally, FDx Advisors Inc. increased its stake in shares of Pfizer by 15.3% in the second quarter. FDx Advisors Inc. now owns 10,707 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 1,419 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. Bank of America decreased their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Royal Bank Of Canada initiated coverage on Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 target price on the stock. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, UBS Group began coverage on Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.05.

Pfizer Stock Performance

Shares of NYSE PFE opened at $26.81 on Tuesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a market cap of $152.42 billion, a P/E ratio of 19.71 and a beta of 0.47. The business’s 50 day moving average is $26.34 and its two-hundred day moving average is $25.48. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the company posted $0.63 earnings per share. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Friday, January 23rd were issued a dividend of $0.43 per share. The ex-dividend date was Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s payout ratio is presently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.